drugset / Trial / NCT00258375

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

NCT00258375

Phase 2 Completed 15 enrolled NCIC Clinical Trials Group
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. OGX-011 may help docetaxel kill more tumor cells by making tumor cells more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving OGX-011 together with docetaxel works in treating women with locally advanced or metastatic breast cancer.

Timeline

Start
2005-10-21
Primary completion
2007-02-23
Completion
2008-09-22

Publications

  • Results Chia S, Dent S, Ellard SL, et al.: A phase II trial of a second generation antisense oligonucleotide (ASO) to clusterin (OGX-011) in combination with docetaxel in metastatic breast cancer (MBC): NCIC-CTG IND 164 trial. [Abstract] American Association for Cancer Research: 98th Annual Meeting, April 14-18, 2007, Los Angeles, CA. A-3512, 2007.

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject custirsen Antisense oligonucleotide Intravenous

Indications